Micropump® (PDF file) is designed for the extended (and/or delayed) release of small chemical drugs via oral administration. It may be used to develop extremely precise pharmacokinetic profiles of single or combination of drugs, in a variety of formats (pill, tablet, capsule, sachet, or liquid).
The description of Micropump, its performance and key advantages are further detailed here.
In addition, Micropump has proven competitive advantages for new pharmaceutical applications:
-
LiquiTime™ allows the extended release liquid formulations of drugs for patients who have difficulty swallowing tablets or capsules, such as children and the elderly.
-
Trigger Lock™ allows the tamper-resistant controlled release formulations of narcotics and other drugs susceptible to abuse.
Micropump-based Products Pipeline
Micropump platform is approved in:
- the USA: the FDA approved Coreg CR®, a controlled release formulation of carvedilol phosphate. Coreg CR microparticles are manufactured by Flamel, and the products is marketed by GlaxoSmithKline in the USA; and,
- Europe: Micropump aspirin, a controlled-release formulation of aspirin (in co-developed in the USA with New Haven Pharmaceuticals as NHP-554).
The description of Micropump, its performance and key advantages are further detailed here.
Trigger Lock is a registered trademark of Flamel Technologies SA.
Coreg CR is registered trademark of GlaxoSmithKline.
